Funding for this research was provided by:
Cancer Research UK (C10604/A25151, C63713/A25951)
Received: 9 May 2020
Revised: 28 June 2020
Accepted: 8 July 2020
First Online: 28 July 2020
Ethics approval and consent to participate
: Patients were recruited in accordance with the declaration of Helsinki and consented to sample storage and use at the University of Leicester Cancer Research Biobank, Research and development project number UHL11274. Ethical approval for the project was via the East Midlands Local Research Ethics Committee (REC: 13/EM/0196).
: Consent for publication is included within the ethics approval from the East Midlands Local Research Ethics Committee (REC: 13/EM/0196). All patients consented to the Leicester biobank study UHL11274 consented for use of their data in publication.
: Data are available in supplementary data files attached. Sequencing data readouts can be requested from the corresponding author.
: The authors declare no competing interests.
: This study was funded by a ‘Hope Against Cancer’, Leicester UK grant [RM60G0494] and in conjunction with the UK Department of Health on an Experimental Cancer Medicine Centre grant [C10604/A25151]. A.A.M., K.P. and D.F.G. are funded by a Cancer Research UK via programme grant to J.A.S. [C63713/A25951]. A.A.M. was also funded by a National Institute for Health Research (NIHR) Academic Clinical Fellowship for this research project.